Chimeric live-attenuated PCV2 vaccine for swine
This technology creates a chimeric virus for use in swine vaccines by combining elements of two different porcine circoviruses. It takes a harmless, non-pathogenic virus (PCV1) and swaps in a specific gene from a highly harmful, pathogenic version (PCV2). The resulting hybrid virus looks like the dangerous version to the pig's immune system, allowing it to build defenses without ever getting sick. This method provides a safer, live-attenuated vaccine platform that effectively prevents Postweaning Multisystemic Wasting Syndrome (PMWS) in livestock.
What you could build
A live-attenuated chimeric vaccine for swine producers and veterinary pharmaceutical companies to prevent PMWS and respiratory disease in commercial pig herds.
Who in Virginia should care
Virginia's substantial swine industry and large-scale livestock pharmaceutical manufacturers (like those in the Shenandoah Valley) would be prime users or license holders.
Readiness: Prototype likely
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
- Granted
- February 13, 2018
- Status
- Granted patent
- Patent number
- 9889187
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.